BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36858078)

  • 1. Synthesis and biological evaluation of N-(3-fluorobenzyl)-4-(1-(methyl-d
    Kang BN; Kang HJ; Kim S; Lee J; Lee J; Jeong HJ; Jeon S; Shin Y; Yoon C; Han C; Seo J; Yun J
    Bioorg Med Chem Lett; 2023 Apr; 85():129205. PubMed ID: 36858078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
    J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
    Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
    Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
    Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor.
    Kim YW; Kim YK; Kim DK; Sheen YY
    Xenobiotica; 2008 May; 38(5):451-64. PubMed ID: 18421620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.
    Kim YW; Kim YK; Lee JY; Chang KT; Lee HJ; Kim DK; Sheen YY
    Xenobiotica; 2008 Mar; 38(3):325-39. PubMed ID: 18274960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors.
    Tan B; Zhang X; Quan X; Zheng G; Li X; Zhao L; Li W; Li B
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127339. PubMed ID: 32631540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel thiazole-derivatives as potent ALK5 inhibitors.
    Arai M; Hanada M; Moriyama H; Ohmoto H; Miyake T; Naka K; Sawa M
    Bioorg Med Chem Lett; 2024 Aug; 108():129797. PubMed ID: 38759932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Krishnaiah M; Jin CH; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.
    Amada H; Asanuma H; Koami T; Okada A; Endo M; Ueda Y; Naruse T; Ikeda A
    Chem Pharm Bull (Tokyo); 2013; 61(3):286-91. PubMed ID: 23449197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Krishnaiah M; Jin CH; Sreenu D; Subrahmanyam VB; Rao KS; Son DH; Park HJ; Kim SW; Sheen YY; Kim DK
    Eur J Med Chem; 2012 Nov; 57():74-84. PubMed ID: 23047226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel ALK5 inhibitor TP0427736 reduces TGF-β induced growth inhibition in human outer root sheath cells and elongates anagen phase in mouse hair follicles.
    Naruse T; Aoki M; Fujimoto N; Arase S; Oura H; Ueda Y; Ikeda A
    Pharmacol Rep; 2017 Jun; 69(3):485-491. PubMed ID: 28324846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Li F; Park Y; Hah JM; Ryu JS
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1083-6. PubMed ID: 23294702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors.
    Wang Z; Zhang Y; Wang H; Wang X; Yu Z; Zhao L
    Bioorg Med Chem Lett; 2022 Apr; 61():128552. PubMed ID: 35051574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jung SH; Lee HS; Dewang PM
    Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
    Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.